Abstract
Human papilloma virus (HPV)-associated oropharyngeal carcinoma (HPV-OPC) is increasing in many countries. It has distinct microscopic and molecular features as well as clinical aspects. As for microscopic view, two subtypes, non-keratinizing squamous cell carcinoma (NKSCC) and hybrid SCC (HSCC), 3 variants of SCC, undifferentiated carcinoma (UC), basaloid carcinoma (BC), and papillary squamous cell carcinoma (PSCC), and 2 histological structures, abrupt keratinizarion and comedo-necrosis among non-maturing island are related with HPV-OPC. As for molecular aspects, HPV-OPC is more likely to have p53 degradation and Rb (retinoblastoma protein) inactivation with resulting p16 up-regulation compared to HPV-unassociated oropharyngeal carcinoma.
Keywords: Detection method, HPV-associated oropharyngeal carcinoma pathological diagnosis, Human papillomavirus (HPV), molecular diagnosis.
Current Cancer Therapy Reviews
Title:Pathology of the HPV-associated Oropharyngeal Carcinoma
Volume: 11 Issue: 1
Author(s): Yuki Fukumura
Affiliation:
Keywords: Detection method, HPV-associated oropharyngeal carcinoma pathological diagnosis, Human papillomavirus (HPV), molecular diagnosis.
Abstract: Human papilloma virus (HPV)-associated oropharyngeal carcinoma (HPV-OPC) is increasing in many countries. It has distinct microscopic and molecular features as well as clinical aspects. As for microscopic view, two subtypes, non-keratinizing squamous cell carcinoma (NKSCC) and hybrid SCC (HSCC), 3 variants of SCC, undifferentiated carcinoma (UC), basaloid carcinoma (BC), and papillary squamous cell carcinoma (PSCC), and 2 histological structures, abrupt keratinizarion and comedo-necrosis among non-maturing island are related with HPV-OPC. As for molecular aspects, HPV-OPC is more likely to have p53 degradation and Rb (retinoblastoma protein) inactivation with resulting p16 up-regulation compared to HPV-unassociated oropharyngeal carcinoma.
Export Options
About this article
Cite this article as:
Fukumura Yuki, Pathology of the HPV-associated Oropharyngeal Carcinoma, Current Cancer Therapy Reviews 2015; 11 (1) . https://dx.doi.org/10.2174/1573394711666150428003428
DOI https://dx.doi.org/10.2174/1573394711666150428003428 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Progress of Reelin in Development, Inflammation and Tissue Remodeling: From Nervous to Visual Systems
Current Molecular Medicine A Synopsis on the Role of Human Papilloma Virus Infection in Cervical Cancer
Current Drug Metabolism Molecular and Genetic Profiling of Prostate Cancer: Implications for Future Therapy
Current Cancer Therapy Reviews Role of Histone Acetylation in Cell Cycle Regulation
Current Topics in Medicinal Chemistry Clinical Approaches Toward Tumor Angiogenesis: Past, Present and Future
Current Pharmaceutical Design Chromatin Modification and Senescence
Current Pharmaceutical Design Studies on Anticancer Activities of Lactoferrin and Lactoferricin
Current Protein & Peptide Science Bone Morphogenetic Proteins and its Receptors; Therapeutic Targets in Cancer Progression and Bone Metastasis?
Current Pharmaceutical Design From Bortezomib to other Inhibitors of the Proteasome and Beyond
Current Pharmaceutical Design Viral and Cellular Cytokines as Therapeutic Targets in AIDS-Related Lymphoproliferative Disorders
Current Drug Targets - Cardiovascular & Hematological Disorders Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs
Current Medicinal Chemistry Advances in the Development of Non-Human Viral DNA-Vectors for Gene Delivery
Current Gene Therapy Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets Recent Progress in the Pharmacology of Imidazo[1,2-a]pyridines
Mini-Reviews in Medicinal Chemistry Employing New Cellular Therapeutic Targets for Alzheimers Disease: A Change for the Better?
Current Neurovascular Research Editorial [Hot Topic: Reprogramming of Normal and Cancer Stem Cells (Guest Editor: Pier Mario Biava)]
Current Pharmaceutical Biotechnology Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Antisense Oligonucleotides as an Innovative Therapeutic Strategy in the Treatment of High-Grade Gliomas
Recent Patents on CNS Drug Discovery (Discontinued) Novel Insights in Molecular Mechanisms of CLL
Current Pharmaceutical Design Sodium Dependent Multivitamin Transporter (SMVT): A Potential Target for Drug Delivery
Current Drug Targets